• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cell-Dependent Activation of ProTide Prodrugs and Its Implications in Antiviral Studies.细胞依赖性原药前体的激活及其在抗病毒研究中的意义。
ACS Pharmacol Transl Sci. 2023 Jul 6;6(10):1340-1346. doi: 10.1021/acsptsci.3c00050. eCollection 2023 Oct 13.
2
Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection.替诺福韦艾拉酚胺和索磷布韦在人肺中的激活及其在开发用于治疗SARS-CoV-2肺部感染的核苷/核苷酸前药中的意义。
Pharmaceutics. 2021 Oct 11;13(10):1656. doi: 10.3390/pharmaceutics13101656.
3
Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.抗新冠病毒核苷及核苷酸前药激活酶的组织特异性蛋白质组学分析为前药设计优化及药物治疗策略提供见解
ACS Pharmacol Transl Sci. 2021 Apr 1;4(2):870-887. doi: 10.1021/acsptsci.1c00016. eCollection 2021 Apr 9.
4
Advancement of Prodrug Approaches for Nucleotide Antiviral Agents.前药策略在核苷酸类抗病毒药物中的研究进展。
Curr Top Med Chem. 2021;21(32):2909-2927. doi: 10.2174/1568026621666210728094019.
5
In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate.替诺福韦艾拉酚胺的体外病毒学特征,替诺福韦的一种新型口服前药,与富马酸替诺福韦二吡呋酯相比具有更高的抗病毒活性。
Antimicrob Agents Chemother. 2015 Oct;59(10):5909-16. doi: 10.1128/AAC.01152-15. Epub 2015 Jul 6.
6
Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.在细胞内浓度超过临床相关药物暴露水平时,替诺福韦艾拉酚胺(TAF)不会消耗人T细胞系中的线粒体DNA。
Antiviral Res. 2017 Apr;140:116-120. doi: 10.1016/j.antiviral.2017.01.014. Epub 2017 Jan 26.
7
Contributions of Cathepsin A and Carboxylesterase 1 to the Hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.组织蛋白酶 A 和羧酸酯酶 1 对人肝内替诺福韦艾拉酚胺水解的贡献,以及 CES1 遗传变异对替诺福韦艾拉酚胺水解的影响。
Drug Metab Dispos. 2022 Mar;50(3):243-248. doi: 10.1124/dmd.120.000323. Epub 2021 Dec 21.
8
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.替诺福韦艾拉酚胺的细胞内激活及病毒和宿主蛋白酶抑制剂的作用
Antimicrob Agents Chemother. 2015 Oct 26;60(1):316-22. doi: 10.1128/AAC.01834-15. Print 2016 Jan.
9
Discovery of Modified Amidate (ProTide) Prodrugs of Tenofovir with Enhanced Antiviral Properties.发现具有增强抗病毒性能的泰诺福韦的修饰酰胺(前药)前药。
J Med Chem. 2021 Nov 25;64(22):16425-16449. doi: 10.1021/acs.jmedchem.1c01444. Epub 2021 Oct 29.
10
Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.P-糖蛋白的作用及与索非布韦联合应用对富马酸替诺福韦二吡呋酯和富马酸替诺福韦艾拉酚胺肠渗透的影响。
Pharm Res. 2023 Sep;40(9):2109-2120. doi: 10.1007/s11095-023-03581-2. Epub 2023 Aug 18.

引用本文的文献

1
Pharmacokinetics and Metabolism of Broad-Spectrum Antivirals Remdesivir and Obeldesivir with a Consideration to Metabolite GS-441524: Same, Similar, or Different?广谱抗病毒药物瑞德西韦和奥贝德西韦的药代动力学与代谢,并对代谢物GS-441524进行考量:相同、相似还是不同?
Viruses. 2025 Jun 10;17(6):836. doi: 10.3390/v17060836.
2
Thio-ProTide strategy: A novel HS donor-drug conjugate (DDC) alleviates hepatic injury innate lysosomal targeting.硫代原钛策略:一种新型的硫化氢供体-药物偶联物(DDC)通过先天性溶酶体靶向减轻肝损伤。
Acta Pharm Sin B. 2024 Dec;14(12):5341-5356. doi: 10.1016/j.apsb.2024.10.017. Epub 2024 Nov 9.
3
Development of robust antiviral assays using relevant apical-out human airway organoids.使用相关的顶端向外的人呼吸道类器官开发强大的抗病毒检测方法。
bioRxiv. 2024 Jul 12:2024.01.02.573939. doi: 10.1101/2024.01.02.573939.
4
Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.核苷类抗病毒药物分子机制的最新进展
Curr Issues Mol Biol. 2023 Aug 17;45(8):6851-6879. doi: 10.3390/cimb45080433.

本文引用的文献

1
Systematic Exploration of SARS-CoV-2 Adaptation to Vero E6, Vero E6/TMPRSS2, and Calu-3 Cells.系统探索 SARS-CoV-2 对 Vero E6、Vero E6/TMPRSS2 和 Calu-3 细胞的适应性。
Genome Biol Evol. 2023 Apr 6;15(4). doi: 10.1093/gbe/evad035.
2
Cell cycle block by p53 activation reduces SARS-CoV-2 release in infected alveolar basal epithelial A549-hACE2 cells.p53激活引起的细胞周期阻滞减少了感染的肺泡基底上皮A549-hACE2细胞中SARS-CoV-2的释放。
Front Pharmacol. 2022 Dec 13;13:1018761. doi: 10.3389/fphar.2022.1018761. eCollection 2022.
3
Predicting and Anti-SARS-CoV-2 Activities of Antivirals by Intracellular Bioavailability and Biochemical Activity.通过细胞内生物利用度和生化活性预测抗病毒药物及抗SARS-CoV-2活性
ACS Omega. 2022 Nov 29;7(49):45023-45035. doi: 10.1021/acsomega.2c05376. eCollection 2022 Dec 13.
4
Phosphoramidate Prodrugs Continue to Deliver, The Journey of Remdesivir (GS-5734) from RSV to SARS-CoV-2.磷酸氨基酯前药持续发挥作用,瑞德西韦(GS-5734)从呼吸道合胞病毒到严重急性呼吸综合征冠状病毒2的历程。
ACS Med Chem Lett. 2022 Feb 21;13(3):338-347. doi: 10.1021/acsmedchemlett.1c00624. eCollection 2022 Mar 10.
5
Deep Time Course Proteomics of SARS-CoV- and SARS-CoV-2-Infected Human Lung Epithelial Cells (Calu-3) Reveals Strong Induction of Interferon-Stimulated Gene Expression by SARS-CoV-2 in Contrast to SARS-CoV.深度时间-course 蛋白质组学研究 SARS-CoV- 和 SARS-CoV-2 感染的人肺上皮细胞(Calu-3),揭示了 SARS-CoV-2 对干扰素刺激基因表达的强烈诱导,与 SARS-CoV 形成对比。
J Proteome Res. 2022 Feb 4;21(2):459-469. doi: 10.1021/acs.jproteome.1c00783. Epub 2022 Jan 4.
6
Aryloxy Pivaloyloxymethyl Prodrugs as Nucleoside Monophosphate Prodrugs.作为单磷酸核苷前药的芳氧基新戊酰氧甲基前药
J Med Chem. 2021 Nov 25;64(22):16703-16710. doi: 10.1021/acs.jmedchem.1c01490. Epub 2021 Nov 4.
7
Activation of Tenofovir Alafenamide and Sofosbuvir in the Human Lung and Its Implications in the Development of Nucleoside/Nucleotide Prodrugs for Treating SARS-CoV-2 Pulmonary Infection.替诺福韦艾拉酚胺和索磷布韦在人肺中的激活及其在开发用于治疗SARS-CoV-2肺部感染的核苷/核苷酸前药中的意义。
Pharmaceutics. 2021 Oct 11;13(10):1656. doi: 10.3390/pharmaceutics13101656.
8
Estimating clinical SARS-CoV-2 infectiousness in Vero E6 and primary airway epithelial cells.评估新型冠状病毒(SARS-CoV-2)在非洲绿猴肾细胞(Vero E6)和原代气道上皮细胞中的临床传染性。
Lancet Microbe. 2021 Nov;2(11):e571. doi: 10.1016/S2666-5247(21)00216-0. Epub 2021 Aug 27.
9
Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS.使用 LC-MS/MS 分析小鼠组织中瑞德西韦代谢物核苷酸单磷酸和三磷酸的生物分析:挑战和逐步适用于目的的优化。
J Pharm Biomed Anal. 2021 Feb 5;194:113806. doi: 10.1016/j.jpba.2020.113806. Epub 2020 Nov 30.
10
Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice.雷迪西韦及其代谢物核苷酸单磷酸、核苷酸三磷酸和核苷在小鼠体内的药代动力学和组织分布。
Acta Pharmacol Sin. 2021 Jul;42(7):1195-1200. doi: 10.1038/s41401-020-00537-9. Epub 2020 Oct 12.

细胞依赖性原药前体的激活及其在抗病毒研究中的意义。

Cell-Dependent Activation of ProTide Prodrugs and Its Implications in Antiviral Studies.

作者信息

Liu Yueting, Sun Shuxin, Li Jiapeng, Wang Weiwen, Zhu Hao-Jie

机构信息

Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 428 Church Street, Ann Arbor, Michigan 48109, United States.

出版信息

ACS Pharmacol Transl Sci. 2023 Jul 6;6(10):1340-1346. doi: 10.1021/acsptsci.3c00050. eCollection 2023 Oct 13.

DOI:10.1021/acsptsci.3c00050
PMID:37854623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10580387/
Abstract

The ProTide prodrug design is a powerful tool to improve cell permeability and enhance the intracellular activation of nucleotide antiviral analogues. Previous in vitro studies showed that the activation of ProTide prodrugs varied in different cell lines. In the present study, we investigated the activation profiles of two antiviral prodrugs tenofovir alafenamide (TAF) and sofosbuvir (SOF) in five cell lines commonly used in antiviral research, namely, Vero E6, Huh-7, Calu-3, A549, and Caco-2. We found that TAF and SOF were activated in a cell-dependent manner with Vero E6 being the least efficient and Huh-7 being the most efficient cell line for activating the prodrugs. We also demonstrated that TAF was activated at a significantly higher rate than SOF. We further analyzed the protein expressions of the activating enzymes carboxylesterase 1, cathepsin A, histidine triad nucleotide-binding protein 1, and the relevant drug transporters P-glycoprotein and organic anion-transporting polypeptides 1B1 and 1B3 in the cell lines using the proteomics data extracted from the literature and proteome database. The results revealed significant differences in the expression patterns of the enzymes and transporters among the cell lines, which might partially contribute to the observed cell-dependent activation of TAF and SOF. These findings highlight the variability of the abundance of activating enzymes and transporters between cell lines and emphasize the importance of selecting appropriate cell lines for assessing the antiviral efficacy of nucleoside/nucleotide prodrugs.

摘要

前药设计是提高细胞通透性和增强核苷酸抗病毒类似物细胞内活化的有力工具。先前的体外研究表明,前药在不同细胞系中的活化情况各不相同。在本研究中,我们调查了两种抗病毒前药替诺福韦艾拉酚胺(TAF)和索磷布韦(SOF)在抗病毒研究中常用的五种细胞系,即Vero E6、Huh-7、Calu-3、A549和Caco-2中的活化情况。我们发现TAF和SOF的活化具有细胞依赖性,其中Vero E6是活化前药效率最低的细胞系,而Huh-7是最有效的细胞系。我们还证明TAF的活化率明显高于SOF。我们利用从文献和蛋白质组数据库中提取的蛋白质组学数据,进一步分析了细胞系中活化酶羧酸酯酶1、组织蛋白酶A、组氨酸三联体核苷酸结合蛋白1以及相关药物转运体P-糖蛋白和有机阴离子转运多肽1B1和1B3的蛋白表达。结果显示,细胞系之间酶和转运体的表达模式存在显著差异,这可能部分解释了观察到的TAF和SOF的细胞依赖性活化。这些发现突出了细胞系之间活化酶和转运体丰度的变异性,并强调了选择合适的细胞系来评估核苷/核苷酸前药抗病毒疗效的重要性。